Clinical Trial

Clinico-biological Data Collection Study of Metastatic Breast Cancer

Study acronym: EPICURE_SEIN
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial. These mechanisms involve clinical and biological factors associated with the host and the tumor and possibly the patient's psycho-social environment. PURPOSE : This trial will assess the use of a prospective database dedicated to patients with breast cancers that contains clinical data as well as epidemiological, psychological, emotional, social, imaging, biological and bio-pathological data. These data will allow a creation of new modelling algorithms in order to predict response and resistance to treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-05-20; most recent amendment 2025-08-13.
Status change: Recruiting → Active, Not Recruiting 2025-08-13
Trial Details
NCT Number NCT03958136
Lead Sponsor Institut Cancerologie de l'Ouest
Collaborators: European Regional Development Fund, AstraZeneca, Novartis, Eli Lilly and Company
Conditions Breast Cancer
Enrollment 289 participants
Start Date 2018-12-24
Primary Completion 2035-12-24 (estimated)
Study Completion 2036-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-17